We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kooth Plc | KOO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -5.00 | -2.89% | 168.00 | 09:34:32 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 173.00 | 168.00 | 173.00 | 168.00 | 173.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 20/10/2024 09:42 by pireric KOO has basically become a 'woke' target in the US. Great timing from the secondary sellers to sell when they did. If Trump wins Presidency and the Republicans gain more ground, it has to be a net negative for Kooth in my view. In any case, I don't love how they're trying to sell mental health services in an equity structure as a high margin SaaS story (that's just the revenue model...).Eric |
Posted at 17/9/2024 06:40 by hatfullofsky Kooth Delivers Record Revenue and Profit in H1 2024Fantastic Results |
Posted at 21/8/2023 14:33 by rimau1 Enough days have passed to now mention that KOO had a detailed write up and buy recommendation in SCSW Aug edition. Interviewed Tim Barker and concluded that the Cali contract execution is now past “peak risk” and Barker identifies North Carolina and NY State as the next opportunities. Barker is also working on the SaaS licensing model for Ex US ex UK geographies. Operational leverage kicking in from 2024, “shares are worth buying on quiet market days, next results in September” |
Posted at 16/7/2023 09:45 by rimau1 Broker note from Liberum - consistent with my valuation assumptions posted last week.Koo, a front-runner in the personalised digital mental health sector, could offer a significant value proposition for investors, according to a recent note by UK brokerage firm Liberum. The company's shares, currently priced at 346p, are undervalued based on Liberum's price target of 457p. But the growth potential doesn't stop there. Liberum points to the potential for more US contracts and licensing opportunities, which could add a further 400p over time, effectively more than doubling the company's share price. The timing couldn't be better for Kooth, as it enters the fray in a world grappling with a mental health crisis. It's one of the few companies with a proven solution to address this, and it's already a market leader in the UK. Recently, the company managed to secure transformational contracts in the US, worth $180 million and indicating its scalability and potential for international expansion. The California deal is a prime example of this, which could potentially triple Kooth's revenue. As the company moves forward, key value drivers will include technology updates for the California contract, scaling up in Pennsylvania and California, and renewing the Pennsylvania contract. However, it should be noted that there is a high execution risk over the next twelve months. Liberum emphasises what the market might be overlooking. The breadth and scalability of Kooth's offerings are difficult to replicate, making it a unique player in the sector. Licensing will also enable Kooth to scale rapidly and with less risk. |
Posted at 14/7/2023 07:22 by rimau1 Hi Nimbo, this stock is my largest holding so i have a very strong bull case! It was the placing that confirmed everything for me because they had previously indicated that they could self-fund Cali and wanted to execute Cali prior to considering further expansion to mitigate execution risk. This has all changed now and i suspect/guess they have been approached by other states so we are rapidly accelerating the growth plans. They have not rsn’d a scope widening of the Penn pilot but i posted an article here that confirmed it was happening to a degree. I am excited about New York which would be hugely significant and likely next. I am also excited on international expansion where we would licence our model out to local providers so the growth could be potentially exponential. I always value Koo on 3.5x ARR based on CFO comments as we are a hybrid SAAS. So with no new state wins we should really be currently valued on fwd/FY24 at £175m all IMO. Well below the radar however IC should help today. |
Posted at 18/4/2023 11:28 by acuere Yes ‘twas good. I’m still unsure if they’re trying for these other States or focussing on getting Cali right. I’d be happy for them to do placing if it meant them being able to win other States.California is biggest state and Penn comes in at 5, but the other 3 mentioned (NY,NC,Va) are all biggies as well. 1 California 38,915,693 2 Texas 30,500,280 3 Florida 22,661,577 4 New York 19,496,810 5 Pennsylvania 12,931,957 6 Illinois 12,477,595 7 Ohio 11,747,774 8 Georgia 11,037,723 9 North Carolina 10,832,061 10 Michigan 10,030,722 11 New Jersey 9,255,437 12 Virginia 8,709,873 The other thing I’d say is if it is even split between workstreams I would expect Koo servicing 13-25yo would command greater share. So possibly $200m over 5 years. |
Posted at 22/1/2023 21:41 by rimau1 Therapists costing 3x more is solved simply by Koo charging 3x more FFS!!!! Koo also set up a local US mgt team it won’t be managed from the UK. Do you have any sensible questions? |
Posted at 22/1/2023 14:38 by rimau1 Last post from me here for a while. They appear (understandably given Kooth UK performance track record) very confident that the Penn pilot will be successful and lead to a larger longer contract which will in turn lead to further state contracts. However practitioners need to be licensed in the state that they operate in so it seems to me Koo will expand state by state rather than multi state roll outs which helps keep a lid on costs and retains focus but obviously takes longer. In terms of ex UK ex US expansion KOO will licence their technology out which is an excellent strategy IMO. Bolt on acquisitions unlikely although they are constantly being approached especially by distressed assets but the KOO model is primarily organic. The other snippet was that the existing cash runway extends for 2 years but in any case they expect to be cash flow positive within 3-6 months. Exciting times. |
Posted at 19/1/2023 08:17 by rimau1 Excellent update. Very below the radar and the significant derating last year was simply due to the growth/tech stock association and unwarranted IMO. KOO are trading on 2 x historic ARR after stripping out net cash which is simply too cheap with sufficient balance sheet strength to find expansion plans. Plenty of clues in this update that the business is doing well; entrenched in the NHS, rolling out in Scotland, interestingly now providing an A&E emergency response to alleviate pressure on A&E and most importantly the US rollout which is historically the amber flag for me (as few businesses succeed in entry)is progressing well. Penn is bedding in and should result in further contract awards. Patience required but this is a high conviction long term hold for me. |
Posted at 16/3/2022 09:13 by rimau1 Great unexpected update. Forward looking ARR should be approaching £18m now so this is looking cheap. To the extent that they can KOO have a monopoly in the UK as they cover c.90% of the young adult market so extending contracts to Adults with the existing customers (NHS trusts) should be almost guaranteed. Lucrative Corporate market excites me. Expansion into the US makes me a little nervous as that has gone quiet since the US hire. Expect an update on US progress before results in Q2. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
